Rafael Holdings logo
Rafael Holdings RFL
$ 2.02 1.0%
report update icon

Quarterly report 2026-Q3
added 06-11-2026

Rafael Holdings Income Statement 2025-2011 | RFL

Brief overview of financial performance at Rafael Holdings

The conclusions below are based on five years of reported results. Rafael Holdings reported revenue of 4.9 million dollars in 2020 and 917 thousand dollars by 2025. The total change was −81.3%, with a CAGR of approximately −28.5%. Revenue ended the period on a sustained downward trend.

EBITDA changed from −6.6 million dollars to −28.9 million dollars (−337.5%). EBITDA underperformed the top-line trend. The EBITDA share of revenue changed from −134.4% to −3148.4%. Operating return per unit of revenue declined.

Comparing the endpoints shows a move from −$10.4 million to −$290 thousand. The negative result improved without reaching break-even.

The market value of the business moved from 265 million dollars to 39.4 million dollars, or −85.1%. Capitalization lags the underlying business improvement.

Overall conclusion

The results contain several connected negative signals. The positive side is supported by net-income growth. Caution is warranted because of a narrow EBITDA buffer, pressure on operating profitability and lower investor confidence. Further direction will depend on top-line growth, operating profitability, and net income.

Annual Income Statement Rafael Holdings

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

39.4 M 31.8 M 40 M 35.8 M 49.6 M 265 M 268 M 117 M - - - - - - -

Shares

29.4 M 23.7 M 23.3 M 19.8 M 16.5 M 15.8 M 13.3 M 12.5 M - - - - - - -

Historical Prices

1.34 1.34 1.72 1.81 3.15 35.8 18.8 15.8 - - - - - - -

Net Income

-290 K -34.4 M -1.88 M -125 M -23.1 M -10.4 M -4.69 M -11.6 M 138 K 710 K - - - - -

Revenue

917 K 637 K 279 K 410 K 802 K 4.91 M 4.93 M 4.37 M 5.62 M 5.59 M - - - - -

Cost of Revenue

- 154 K - 3.5 M 3.17 M - - - 993 K - - - - - -

Operating Income

-29.2 M -103 M -15 M -60.5 M -28.2 M -8.46 M -6.7 M -3.84 M 221 K 1.19 M - - - - -

Interest Expense

658 K 248 K - 6 K 12 K -32 K 469 K 16 K 10 K -20 K - - - - -

EBITDA

-28.9 M -102 M -15 M -60.4 M -28.1 M -6.6 M -4.92 M -2.14 M 1.89 M 2.84 M - - - - -

Operating Expenses

- - - - - 13.4 M 11.6 M 8.21 M - - - - - - -

General and Administrative Expenses

1.96 M 2 M 3.04 M 17.3 M 6.11 M 9.12 M 8.82 M 5.52 M - - - - - - -

All numbers in USD currency

Quarterly Income Statement Rafael Holdings

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

51.2 M 51.2 M 51.2 M 51.2 M 25.2 M 24.2 M 25.2 M 24.2 M 24.1 M 23.6 M 23.8 M 23.6 M 23.2 M 23.4 M 19.7 M 23 M - 19.8 M 16.2 M 18.9 M 16 M 16.7 M 15.8 M 15.8 M 15.7 M 15.8 M 13.5 M 15.6 M 12.6 M 15.6 M 12.5 M 12.6 M 12.5 M 12.5 M - 12.5 M - 12.5 M - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-4.23 M -6.42 M -9.82 M -6.42 M -4.78 M -4.64 M -4.78 M -4.64 M -9.01 M 6.05 M -32.4 M -3.64 M -3.25 M -1.44 M -2.56 M 1.59 M - -5.55 M -8.24 M -129 M -9.67 M -2.65 M -1.25 M -1.43 M -2.85 M -1.43 M -1.02 M -1.6 M -1.5 M -1.6 M -546 K -481 K -635 K -481 K 166 K -9.33 M -91 K -65 K - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

179 K 211 K 240 K 211 K 362 K 77 K 362 K 77 K 128 K 68 K 336 K 68 K 70 K 71 K 70 K 70 K - 76 K 74 K 191 K 2.01 M 990 K 1.24 M 1.05 M 2.45 M 1.05 M 1.02 M 1.21 M 2.15 M 1.21 M 956 K 1.14 M 1.22 M 1.14 M 1.34 M 1.11 M 1.6 M 1.28 M - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - - - 294 K 38 K - - 37 K 290 M 85 K - 249 K - - 249 K - 799 K - 835 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-6.87 M -6.66 M -10.1 M -6.66 M -5.91 M -6.64 M -5.91 M -6.64 M -3.84 M -3.14 M -93.2 M -2.48 M -4.26 M -3.03 M -1.71 M -5.14 M - -4.69 M -10.8 M -49.5 M -13.3 M -3.48 M -1.91 M -2.49 M -3.45 M -2.49 M -1.41 M -1.54 M -2.53 M -1.54 M -816 K -1.12 M -1.24 M -1.12 M 127 K -1.06 M 100 K -164 K - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

-25 K -1 K 160 K -1 K 165 K 163 K 165 K -78 K 162 K - 85 K 93 K 13 K - - - - 1 K -1 K 13 K - 3 K 33 K -31 K -31 K - 767 K -64 K 868 K -64 K 2 K 101 K 4 K 101 K 2 K 2 K 7 K 1 K - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-6.82 M -6.6 M -10.1 M -6.6 M -5.85 M -6.55 M -5.85 M -6.55 M -3.76 M -3.1 M -93.1 M -2.46 M -4.22 M -3.01 M -1.33 M -5.12 M - -4.67 M -10.4 M -49.5 M -12.4 M -3.28 M -1.43 M -2.05 M -2.51 M -2.05 M -975 K -1.08 M -1.67 M -1.08 M -387 K -691 K -388 K -691 K 561 K -630 K 922 K 247 K - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

150 K 343 K 170 K 343 K 308 K 464 K 308 K 464 K 320 K 667 K 443 K 508 K 2.08 M 564 K 7.76 M 3.11 M - 928 K 400 K 12.3 M 507 K 112 K 2.22 M 2.59 M 4.26 M 2.59 M 1.72 M 2.04 M 3.17 M 2.04 M 1.34 M 1.45 M 3.08 M 1.45 M 776 K 1.74 M 1.63 M 1.04 M - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Rafael Holdings (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 1.31 6.5 % $ 166 M schweizSchweiz
ADMA Biologics ADMA Biologics
ADMA
$ 9.7 3.21 % $ 2.31 B usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 27.89 0.3 % $ 4.23 B usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 13.3 1.06 % $ 364 M israelIsrael
AbbVie AbbVie
ABBV
$ 265.08 0.02 % $ 469 B usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 193.45 0.24 % $ 9.62 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.28 2.24 % $ 28.1 M usaUSA
Adagene Adagene
ADAG
$ 2.97 0.62 % $ 175 M chinaChina
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 5.53 2.65 % $ 293 M usaUSA
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 4.04 0.24 % $ 2.7 M usaUSA
Evelo Biosciences Evelo Biosciences
EVLO
- -14.46 % $ 27.9 M usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 62.21 0.06 % $ 11.9 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.85 0.2 % $ 929 M canadaCanada
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.16 0.45 % $ 3.56 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 7.83 0.87 % $ 341 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 14.19 1.17 % $ 1.27 B usaUSA
Amryt Pharma plc Amryt Pharma plc
AMYT
- - $ 621 M britainBritain
C4 Therapeutics C4 Therapeutics
CCCC
$ 3.08 0.3 % $ 255 M usaUSA
Codexis Codexis
CDXS
$ 1.38 0.72 % $ 120 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 2.6 4.3 % $ 496 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.26 1.48 % $ 148 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 31.12 0.28 % $ 2.07 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 4.04 4.94 % $ 49.3 M israelIsrael
AbCellera Biologics AbCellera Biologics
ABCL
$ 12.31 0.12 % $ 3.68 B canadaCanada
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 5.26 2.69 % $ 645 M usaUSA
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
$ 1.19 1.26 % $ 13.4 M usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 22.45 1.05 % $ 711 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 112.94 3.29 % $ 11.7 B usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 7.74 0.19 % $ 103 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.31 0.74 % $ 87.6 M usaUSA
Curis Curis
CRIS
$ 0.95 0.98 % $ 12.5 M usaUSA
CorMedix CorMedix
CRMD
$ 7.69 0.06 % $ 554 K usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 55.76 1.2 % $ 5.01 B schweizSchweiz
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 12.54 8.21 % $ 990 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Cue Biopharma Cue Biopharma
CUE
$ 31.71 2.62 % $ 3 B usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
$ 1.68 0.59 % $ 13.5 M usaUSA
Cytokinetics, Incorporated Cytokinetics, Incorporated
CYTK
$ 65.81 0.04 % $ 7.9 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 450.61 1.61 % $ 35.2 B usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
DiaMedica Therapeutics DiaMedica Therapeutics
DMAC
$ 7.56 7.16 % $ 355 M usaUSA
Denali Therapeutics Denali Therapeutics
DNLI
$ 20.46 5.52 % $ 3.53 B usaUSA
Precision BioSciences Precision BioSciences
DTIL
$ 6.36 10.62 % $ 81.6 M usaUSA
Dyadic International Dyadic International
DYAI
$ 0.41 3.72 % $ 14.8 M usaUSA
Editas Medicine Editas Medicine
EDIT
$ 2.69 0.17 % $ 239 M usaUSA
Edesa Biotech Edesa Biotech
EDSA
$ 3.97 1.46 % $ 22.5 M usaUSA